Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy
Table 2
Vaginal health score.
groups
baseline
4 weeks
8 weeks
12 weeks
4 weeks after drug withdrawal
p1
p2
p3
p4
VHS
treatment group
9.87±2.33
12.00±1.81
13.10±1.79
14.64±1.37
13.41±1.37
<0.001
<0.001
<0.001
<0.001
placebo group
10.44±2.35
10.44±2.32
10.36±2.31
10.39±2.13
10.42±2.29
1.000
0.370
0.640
0.560
p
0.245
0.002
<0.001
<0.001
<0.001
elasticity
treatment group
2.18±0.56
2.21±0.57
2.31±0.57
2.82±0.39
2.77±0.43
0.32
0.03
<0.001
<0.001
placebo group
2.25±0.55
2.25±0.55
2.22±0.54
2.22±0.54
2.22±0.54
1.000
0.320
0.320
0.320
p
0.585
0.744
0.484
<0.001
<0.001
moisture
treatment group
2.00±0.76
2.59±0.55
2.90±0.60
3.08±0.42
2.85±0.54
<0.001
<0.001
<0.001
<0.001
placebo group
2.08±0.73
2.08±0.73
2.08±0.73
2.11±0.71
2.11±0.75
1.000
1.000
0.320
0.320
p
0.700
0.001
<0.001
<0.001
<0.001
pH
treatment group
1.92±0.66
2.10±0.60
2.23±0.67
2.59±0.59
2.54±0.60
<0.001
<0.001
<0.001
<0.001
placebo group
1.89±0.71
1.94±0.71
1.94±0.67
1.92±0.69
1.92±0.73
0.160
0.160
0.320
0.320
p
0.810
0.305
0.081
<0.001
<0.001
mucosa
treatment group
1.95±0.89
2.54±0.60
2.77±0.48
2.97±0.28
2.85±0.43
<0.001
<0.001
<0.001
<0.001
placebo group
2.14±0.72
2.08±0.69
2.03±0.61
2.08±0.55
2.06±0.58
0.160
0.160
0.480
0.260
p
0.330
0.004
<0.001
<0.001
<0.001
discharge
treatment group
1.82±0.68
2.56±0.55
2.90±0.45
3.18±0.39
2.41±0.50
<0.001
<0.001
<0.001
<0.001
placebo group
2.08±0.73
2.08±0.73
2.08±0.73
2.06±0.67
2.11±0.75
1.000
1.000
0.560
0.320
p
0.127
0.002
<0.001
<0.001
0.048
P: significant difference between the treatment and placebo groups. P1: significant difference in score and baseline between the treatment and placebo groups after 4 weeks of medication. P2: significant difference in score and baseline between the treatment and placebo groups after 8 weeks of medication. P3: significant difference in score and baseline between the treatment and placebo groups after 12 weeks of medication. P4: significant difference in score and baseline between the treatment and placebo groups 4 weeks after drug withdrawal.
